Citigroup Inc Passage Bio, Inc. Transaction History

Citigroup Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$0.86 - $1.73 $712 - $1,434	-829 Reduced 17.28%	3,969 $5,000
Q4 2023 Feb 09, 2024	BUY	$0.6 - $1.01 $2,878 - $4,845	4,798 New	4,798 $4,000
Q4 2022 Feb 09, 2023	SELL	$1.06 - $1.48 $696 - $972	-657 Reduced 76.84%	198 $0
Q3 2022 Nov 10, 2022	SELL	$1.22 - $2.48 $879 - $1,788	-721 Reduced 45.75%	855 $1,000
Q2 2022 Aug 10, 2022	SELL	$1.63 - $3.46 $64,389 - $136,680	-39,503 Reduced 96.16%	1,576 $4,000
Q1 2022 May 12, 2022	SELL	$2.66 - $6.49 $60,336 - $147,212	-22,683 Reduced 35.57%	41,079 $127,000
Q4 2021 Feb 10, 2022	BUY	$6.24 - $10.2 $54,044 - $88,342	8,661 Added 15.72%	63,762 $405,000
Q3 2021 Nov 10, 2021	BUY	$9.73 - $15.52 $536,132 - $855,167	55,101 New	55,101 $549,000

38.7M

7.7K

Ticker PASG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,463,200
Market Cap $32.1M
Description
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.